keyword
https://read.qxmd.com/read/38648832/management-of-type-2-diabetes-mellitus-with-noninsulin-pharmacotherapy
#1
JOURNAL ARTICLE
Elizabeth M Vaughan, Zuleica M Santiago-Delgado
Type 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Association class III or IV heart failure...
April 2024: American Family Physician
https://read.qxmd.com/read/38569758/efficacy-and-safety-of-dapagliflozin-in-patients-with-acute-heart%C3%A2-failure
#2
RANDOMIZED CONTROLLED TRIAL
Zachary L Cox, Sean P Collins, Gabriel A Hernandez, A Thomas McRae, Beth T Davidson, Kirkwood Adams, Mark Aaron, Luke Cunningham, Cathy A Jenkins, Christopher J Lindsell, Frank E Harrell, Christina Kampe, Karen F Miller, William B Stubblefield, JoAnn Lindenfeld
BACKGROUND: The primary goals during acute heart failure (AHF) hospitalization are decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics or other GDMT, early dapagliflozin initiation could achieve both AHF goals. OBJECTIVES: The authors aimed to assess the diuretic efficacy and safety of early dapagliflozin initiation in AHF. METHODS: In a multicenter, open-label study, 240 patients were randomized within 24 hours of hospital presentation for hypervolemic AHF to dapagliflozin 10 mg once daily or structured usual care with protocolized diuretic titration until day 5 or hospital discharge...
April 9, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38563191/association-between-neutrophil-to-lymphocyte-ratio-and-outcomes-in-hospitalized-patients-with-left-ventricular-thrombus
#3
JOURNAL ARTICLE
Yingxia Che, Shenglan Huang, Wei Zhou, Shunyi Shi, Fei Ye, Yuan Ji, Jun Huang
BACKGROUND: Left ventricular thrombus (LVT) is a severe cardiovascular complication occurring in approximately 10% of patients with acute anterior ST-segment elevation myocardial infarction. This study aimed to evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and in-hospital major adverse cardiovascular and cerebrovascular events (MACCE) in patients with LVT. MATERIAL AND METHODS: This multicenter retrospective study was conducted between January 2000 and June 2022 in hospitalized patients with LVT...
April 1, 2024: Coronary Artery Disease
https://read.qxmd.com/read/38548513/serum-potassium-abnormalities-renin-angiotensin-aldosterone-system-inhibitor-discontinuation-and-clinical-outcomes-in-patients-with-chronic-cardiovascular-metabolic-and-renal-conditions-a-population-based-analysis
#4
JOURNAL ARTICLE
Santiago Jiménez-Marrero, Miguel Cainzos-Achirica, David Monterde, Emili Vela, Cristina Enjuanes, Sergi Yun, Alberto Garay, Pedro Moliner, Miriam Corbella, Sílvia Jovells-Vaqué, Lídia Alcoberro, Alexandra Pons-Riverola, Raul Ramos-Polo, Herminio Morillas, Joan Antoni Gómez-Hospital, Josep Comin-Colet
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASIs) play a crucial role in the treatment of several chronic cardiovascular conditions. Nonetheless, hyperkalemia, a frequent side effect, often leads to the discontinuation of RAASIs. The implications of hyperkalemia-driven changes in RAASI medications are poorly understood. METHODS: Population-based, observational, retrospective cohort study. Two large healthcare databases were utilized to identify 77,089 individuals aged 55 years and older with chronic conditions who were prescribed RAASIs between 2015 and 2017 in Southern Barcelona, Spain...
March 27, 2024: European Journal of Internal Medicine
https://read.qxmd.com/read/38521648/association-of-cabozantinib-dose-reductions-for-toxicity-with-clinical-effectiveness-in-metastatic-renal-cell-carcinoma-mrcc-results-from-the-canadian-kidney-cancer-information-system-ckcis
#5
JOURNAL ARTICLE
Jeffrey Graham, Sunita Ghosh, Rodney H Breau, Lori Wood, Simon Tanguay, Dominick Bosse, Aly-Khan Lalani, Bimal Bhindi, Daniel Heng, Antonio Finelli, Nazanin Fallah-Rad, Vincent Castonguay, Naveen S Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A Bjarnason
BACKGROUND: Cabozantinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated efficacy in metastatic renal cell carcinoma (mRCC). The association between toxicity and therapeutic effectiveness has been established with other TKIs. We investigated whether cabozantinib dose reductions, a surrogate for toxicity and adequate drug exposure, were associated with improved clinical outcomes in mRCC. METHODS: Employing the CKCis database, we analyzed patients treated with cabozantinib in the second line or later between 2011 to 2021...
February 23, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38465515/pharmacokinetics-and-tolerability-of-a-single-dose-of-apraglutide-a-novel-long-acting-synthetic-glucagon-like-peptide-2-analog-with-a-unique-pharmacologic-profile-in-individuals-with-impaired-renal-function
#6
JOURNAL ARTICLE
Gérard Greig, Nader N Youssef, Federico Bolognani
Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS-IF). Glucagon-like peptide-2 analogs, such as apraglutide, have been developed as a treatment option for SBS-IF. This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function. In this phase 1, open-label, multicenter, nonrandomized, parallel-group study, a single dose of apraglutide 5 mg was administered subcutaneously to individuals with severely impaired renal function (<30 mL/min/1...
March 11, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38456106/predictors-of-treatment-failure-and-mortality-among-patients-with-septic-shock-treated-with-meropenem-in-the-intensive-care-unit
#7
JOURNAL ARTICLE
Mohd Zulfakar Mazlan, Amar Ghassani Ghazali, Mahamarowi Omar, Najib Majdi Yaacob, Nik Abdullah Nik Mohamad, Mohamad Hasyizan Hassan, Wan Fadzlina Wan Muhd Shukeri
BACKGROUND: The aim of the study was to determine the predictors of meropenem treatment failure and mortality in the Intensive Care Unit (ICU). METHODS: This was a retrospective study, involving sepsis and septic shock patients who were admitted to the ICU and received intravenous meropenem. Treatment failure is defined as evidence of non-resolved fever, non-reduced total white cell (TWC), non-reduced C-reactive protein (CRP), subsequent culture negative and death in ICU...
February 2024: Malaysian Journal of Medical Sciences: MJMS
https://read.qxmd.com/read/38445435/association-between-urinary-cobalt-exposure-and-kidney-stones-in-u-s-adult-population-results-from-the-national-health-and-nutrition-examination-survey
#8
JOURNAL ARTICLE
Jun Lu, Dongmei Hong, Qian Wu, Yinghui Xia, Guozhong Chen, Tie Zhou, Cheng Li
PURPOSE: Heavy metal exposure can cause impaired or reduced pathology in the kidneys, lungs, liver, and other vital organs. However, the relationship between heavy metal exposure and kidney stones has not been determined. The goal of this research was to determine the association between heavy metal exposure and kidney stones in a population of American adults in general. MATERIALS AND METHODS: We evaluated 29,201 individuals (≥20 years) from the National Health and Nutrition Examination Survey (NHANES)...
December 2024: Renal Failure
https://read.qxmd.com/read/38429114/association-between-person-centred-care-quality-and-advance-care-planning-participation-in-haemodialysis
#9
JOURNAL ARTICLE
Yusuke Kanakubo, Noriaki Kurita, Mamiko Ukai, Tetsuro Aita, Ryohei Inanaga, Atsuro Kawaji, Takumi Toishi, Masatoshi Matsunami, Yu Munakata, Tomo Suzuki, Tadao Okada
OBJECTIVE: Person-centred care (PCC), which incorporates patients' preferences and values for medical care and their life, has been proposed in decision-making for promoting advance care planning (ACP) among patients with kidney failure. Therefore, we aimed to examine variations in PCC across facilities and the association between PCC and ACP participation. METHODS: This multicentre cross-sectional study included Japanese adults undergoing outpatient haemodialysis at six dialysis centres...
March 1, 2024: BMJ Supportive & Palliative Care
https://read.qxmd.com/read/38357758/association-between-estimated-pulse-wave-velocity-and-in-hospital-mortality-of-patients-with-acute-kidney-injury-a-retrospective-cohort-analysis-of-the-mimic-iv-database
#10
JOURNAL ARTICLE
Xinhai Cui, Yuanlong Hu, Dongxiao Li, Mengkai Lu, Zhiyuan Zhang, Dongfang Kan, Chao Li
BACKGROUND: Estimated pulse wave velocity (ePWV) has been found to be an independent predictor of cardiovascular mortality and kidney injury, which can be estimated noninvasively. This study aimed to investigate the association between ePWV and in-hospital mortality in critically ill patients with acute kidney injury (AKI). METHODS: This study included 5960 patients with AKI from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The low and high ePWV groups were compared using a Kaplan-Meier survival curve to evaluate the differences in survival status...
December 2024: Renal Failure
https://read.qxmd.com/read/38355374/daprodustat-for-post-transplant-anemia-in-renal-transplant-recipients
#11
JOURNAL ARTICLE
Yuichi Machida, Tomoaki Iwai, Kazuya Kabei, Toshihide Naganuma, Junji Uchida
BACKGROUND: Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has been reported to be effective in treating conservative renal failure and renal anemia in patients undergoing dialysis. However, its effects on post-transplant anemia have not yet been reported. This study aimed to determine whether daprodustat may be a useful treatment for post-transplant anemia. MATERIALS: Excluding 5 cases in which the drug was discontinued due to side effects, 21 post-transplant patients treated with daprodustat for ≥12 months and available for follow-up were analyzed...
February 13, 2024: Transplantation Proceedings
https://read.qxmd.com/read/38344757/development-of-a-physiologically-based-pharmacokinetic-model-for-levetiracetam-in-patients-with-renal-impairment-to-guide-dose-adjustment-based-on-steady-state-peak-trough-concentrations
#12
JOURNAL ARTICLE
Rongrong Wang, Tianlin Wang, Xueliang Han, Mengli Chen, Shu Li
1. Levetiracetam may cause acute renal failure and myoclonic encephalopathy at high plasma levels, particularly in patients with renal impairment. The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict levetiracetam pharmacokinetics in Chinese adults with epilepsy and renal impairment and to define appropriate levetiracetam dosing regimen.2. PBPK models for healthy subjects and epilepsy patients with renal impairment were developed, validated and adapted. Furthermore, we predicted the steady-state trough and peak concentrations of levetiracetam in patients with renal impairment using the final PBPK model, thereby recommending appropriate levetiracetam dosing regimens for different renal function stages...
February 12, 2024: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/38337544/-helicobacter-pylori-eradication-therapy-in-patients-with-decreased-renal-function-a-systematic-review
#13
REVIEW
Toshihiro Nishizawa, Masaya Sano, Osamu Toyoshima, Hidekazu Suzuki
Background : There are concerns that Helicobacter pylori eradication therapy may worsen kidney function in patients with decreased renal function. This study aimed to systematically review the literature regarding Helicobacter pylori eradication in patients with renal impairment. Methods : PubMed, the Cochrane Library, and Igaku Chuo Zasshi were searched for comparative studies on H. pylori eradication in patients with renal impairment. Results : Five articles were included in this systematic review. According to a randomized trial comparing a proton pump inhibitor (PPI) + clarithromycin + metronidazole and PPI + clarithromycin + amoxicillin in patients with decreased renal function, the incidence of acute renal failure was significantly lower in PPI + clarithromycin + metronidazole (2%: 1/44) than in PPI + clarithromycin + amoxicillin (18%: 8/44)...
February 1, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38331252/vaccination-and-the-risk-of-post-acute-sequelae-after-covid-19-in-the-omicron-predominant-period
#14
JOURNAL ARTICLE
Kyungmin Huh, Young-Eun Kim, Gi Hwan Bae, Jong Youn Moon, Ji-Man Kang, Jacob Lee, Jang-Whan Bae, Kyong Ran Peck, Jaehun Jung
OBJECTIVES: To assess the association of primary and third doses of vaccination with the risk of post-acute sequelae of COVID-19. METHODS: This retrospective cohort study utilized a combined database of nationwide healthcare claims data, COVID-19 patient registry, and vaccination records from South Korea. Individuals diagnosed with COVID-19 in the Omicron variant-dominant period of January to March 2022 were tracked for 30-120 days post-infection. The exposure of interest was the receipt of primary and third doses of the SARS-CoV-2 vaccine...
February 6, 2024: Clinical Microbiology and Infection
https://read.qxmd.com/read/38321324/syndrome-of-irreversible-lithium-effectuated-neurotoxicity-silent-a-preventable-cerebellar-disorder
#15
JOURNAL ARTICLE
Sarah Marmol, Nestor Beltre, Jason Margolesky
We report a case study of a 60-year-old man with bipolar disorder on stable lithium treatment who developed severe toxicity while admitted to ICU with sepsis and multiorgan failure. Despite unchanged lithium administration, his serum levels escalated due to renal dysfunction, resulting in lithium toxicity. After regaining consciousness, he exhibited a cerebellar syndrome marked by ataxia, tremor, and scanning speech. MRI revealed cerebellar atrophy. Following discontinuation of lithium and hemodialysis, the patient's symptoms remained static...
February 7, 2024: Cerebellum
https://read.qxmd.com/read/38318718/cost-effectiveness-analysis-of-sodium-zirconium-cyclosilicate-for-hyperkalemia-among-patients-with-chronic-kidney-disease-or-heart-failure-in-kuwait
#16
JOURNAL ARTICLE
Gihan Hamdy Elsisi, Mohamed M Ibrahim, Khaldoon Al-Humood, Anas Al-Yousef
INTRODUCTION: Our model was conducted from Kuwaiti payer's perspective to provide evidence on the cost-effectiveness of Sodium zirconium cyclosilicate (SZC) versus patiromer to correct and maintain serum potassium (K+) in combination with renin-angiotensin-aldosterone system inhibitors (RAASis) with different dose titration in patients with chronic kidney disease/heart failure (CKD/HF) with/without renal replacement therapy (RRT). METHODOLOGY: The model was developed as a patient-level, fixed-time increment stochastic simulation to simulate the complexity of disease, including multiple coexisting and competing conditional risks...
February 6, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38311833/results-from-a-phase-1-study-assessing-the-pharmacokinetics-of-the-aldosterone-synthase-inhibitor-baxdrostat-in-participants-with-varying-degrees-of-renal-function
#17
JOURNAL ARTICLE
Mason W Freeman, Yuan-Di Halvorsen, Mary Bond, Brian Murphy, Jonathan Isaacsohn
Baxdrostat is a selective small-molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open-label, parallel-group study assessed the safety and pharmacokinetics (PK) of baxdrostat in participants with varying degrees of renal function. Participants were enrolled into control (estimated glomerular filtration rate [eGFR] ≥60 mL/min), moderate to severe renal impairment (eGFR 15-59 mL/min), or kidney failure (eGFR <15 mL/min) groups and received a single 10-mg baxdrostat dose followed by 7 days of inpatient PK blood and urine sampling...
February 4, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38286409/necessity-of-tobramycin-trough-levels-in-once-daily-iv-treatment-in-patients-with-cystic-fibrosis
#18
JOURNAL ARTICLE
Anne Schlegtendal, Sophia Rettberg, Christoph Maier, Folke Brinkmann, Cordula Koerner-Rettberg
BACKGROUND: Once daily intravenous (iv) treatment with tobramycin for Pseudomonas aeruginosa infection in patients with cystic fibrosis (pwCF) is frequently monitored by measuring tobramycin trough levels (TLs). Although the necessity of these TLs is recently questioned in pwCF without renal impairment, no study has evaluated this so far. The aim of this observational study was to evaluate the frequency of increased tobramycin TLs in pwCF treated with a once daily tobramycin dosing protocol...
January 29, 2024: Klinische Pädiatrie
https://read.qxmd.com/read/38276101/comparing-survival-outcomes-between-hemodialysis-and-hemodiafiltration-using-real-world-data-from-brazil
#19
JOURNAL ARTICLE
Erica Pires da Rocha, Christiane Akemi Kojima, Luis Gustavo Modelli de Andrade, Daniel Monte Costa, Andrea Olivares Magalhaes, Whelington Figueiredo Rocha, Leonardo Nunes de Vasconcelos Junior, Maria Gabriela Rosa, Carolina Steller Wagner Martins
The CONVINCE trial demonstrates that high-dose hemodiafiltration offers a survival advantage for patients in the high-flux hemodiafiltration group compared to hemodialysis. We compared the outcomes of hemodialysis and hemodiafiltration using real-world data. We conducted an analysis on a cohort of patients who underwent hemodiafiltration therapy (HDF) at a single center, NefroStar Clinics. The results obtained were then compared with data from patients receiving hemodialysis (HD) therapy within the Brazilian Public Health System (SUS)...
January 19, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38247339/valacyclovir-neurotoxicity-in-patients-with-end-stage-renal-disease-two-cases-reviewed
#20
JOURNAL ARTICLE
Bernadette Gublo, Amy Beth St Amand, Anupama Menon, Alissa A Scalise
Purpose: The objective of this case series is to highlight different manifestations of valacyclovir associated neurotoxicity (VAN) and demonstrate the importance of adjusting medication appropriately in patients with end-stage renal disease (ESRD) on hemodialysis to prevent these complications. Summary: Valacyclovir is a medication used to treat herpes zoster infection, commonly known as shingles. Valacyclovir is renally cleared and can accumulate in patients with renal dysfunction leading to severe side effects due to the prolonged half-life...
February 2024: Journal of Pharmacy Practice
keyword
keyword
86487
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.